NKT cell costimulation: experimental progress and therapeutic promise.

van den Heuvel MJ, Garg N, Van Kaer L, Haeryfar SM
Trends Mol Med. 2011 17 (2): 65-77

PMID: 21087900 · PMCID: PMC3616392 · DOI:10.1016/j.molmed.2010.10.007

Invariant natural killer T (iNKT) cells are innate lymphocytes with unique specificity for glycolipid antigens and remarkable immunomodulatory properties. The role of costimulatory interactions in iNKT cell responses has recently come under scrutiny. Although iNKT cells and their prototype glycolipid agonist α-galactosylceramide (α-GalCer) have shown promise in several clinical trials conducted in patients with cancer or viral diseases, current iNKT cell-based therapies are far from effective. The concomitant targeting of T cell receptors (TCRs) and costimulatory molecules on iNKT cells represents an exciting new opportunity to optimize such therapeutic approaches. Here, we review recent advances in our understanding of iNKT cell costimulation and discuss potential treatment modalities based on the responsiveness of iNKT cells to disease-tailored glycolipids and select costimulatory ligands.

Copyright © 2010 Elsevier Ltd. All rights reserved.

MeSH Terms (9)

Animals Antigens, Differentiation Gene Expression Regulation Humans Immunotherapy Lymphocyte Activation Natural Killer T-Cells Proto-Oncogene Proteins Signal Transduction

Connections (1)

This publication is referenced by other Labnodes entities: